Semaglutide vs. tirzepatide: reading SURMOUNT-5
A direct comparison answers the weight-loss question more clearly. It still leaves the personal care decision open.
Read the evidencePeptide Routes / ResearchRead the evidence.
Read the evidence.
See the boundaries.
Peptides and GLP-1 research, explained for the decisions in front of you. Start with the question, then follow the evidence.
Featured study · Treatment comparisons
Semaglutide vs. tirzepatide: reading SURMOUNT-5
A direct comparison answers the weight-loss question more clearly. It still leaves the personal care decision open.
Read the study explainerAt week 72. Studied doses in adults with obesity without diabetes; not a prediction of individual results.
Semaglutide and heart risk: what SELECT established
Why a 20% relative reduction and a 1.5 percentage-point absolute difference describe the same trial from different angles.
Read the evidenceSemaglutide weight loss: STEP 1 and what happened after stopping
The initial trial and its follow-up answer different questions about treatment, averages and maintaining a result.
Read the evidenceCompounded vs. approved GLP-1s: what evidence transfers?
The same ingredient name is not the same evidence package. Here is how to separate product identity, regulatory review and a care offer.
Read the evidenceBPC-157 benefits: what human research actually shows
Promising biology is not the same as proven recovery. A closer look at the human knee-pain report, animal research and unresolved safety questions.
Read the evidenceGHK-Cu benefits and side effects: topical vs. injectable evidence
A small skin-care trial and laboratory delivery studies do not establish the benefits or safety of injected copper peptides.
Read the evidencePeptides for weight loss: which evidence belongs to which treatment?
Approved obesity medicines, specialized treatments and investigational peptides answer different questions. Start with the product and the outcome.
Read the evidenceTesamorelin benefits: visceral fat is not the same as weight loss
A specific approved indication, a measurable visceral-fat outcome, and clear limits on what those findings mean for general fat loss.
Read the evidenceSermorelin benefits: what small human studies can—and cannot—show
Historical approval, hormone measurements and early adult studies do not add up to established anti-aging or weight-loss benefits.
Read the evidenceWhat GLP-1 evidence tells you about a provider
A trial, a prescribed product and a care subscription answer three different questions. Learn to keep them separate.
Read the guideEvidence first. Practical choices next.
Research can inform a clinical conversation. Our comparisons help with the service, support and payment questions around it.